The Roots Analysis team is putting in its best effort to offer our clients / readers a reliable source of information, regarding how the pharmaceutical and biotech sectors are coping in the midst of the COVID-19 pandemic. Our intention is to generate realistic insights, based on a variety of factors, which are anticipated to influence both prevalent and future market dynamics. Reach out to us for any help.

CD47 Targeting Therapeutics Market by Target Disease Indication (Acute Myeloid Leukemia, Non-Hodgkin Lymphoma, Colorectal Cancer, Diffuse Large B-cell Lymphoma, Myelodysplastic Syndromes, Non-Small Cell Lung Cancers, Ovarian Epithelial Cancer, Oral Muscositis, Small Cell Lung Cancers), Type of Molecule (Biologics and Small Molecule) Key Players and Key Geographical Regions (US, France, Germany, Italy, Spain, UK, Australia, China, India and Israel): Industry Trends and Global Forecasts, 2021-2035

  • Lowest Price Guaranteed From USD 5,499

  • Published
    October 2021

  • Pages
    104

  • View Count
    221

Example Insights

CD-47-Targeting-Therapeutics-Market-Context CD-47-Targeting-Therapeutics-Market-List CD-47-Targeting-Therapeutics-Market-Distribution CD-47-Targeting-Therapeutics-Market-Partnerships-and-Collaborations
CD-47-Targeting-Therapeutics-Market-Funding-and-Investments CD-47-Targeting-Therapeutics-Market-Clinical-Trial-Analysis CD-47-Targeting-Therapeutics-Market-Key-Opinion-Leaders CD-47-Targeting-Therapeutics-Market-Start-up-Health-Indexing
CD-47-Targeting-Therapeutics-Market-Publication-Analysis CD-47-Targeting-Therapeutics-Market-Big-Pharma-Players CD-47-Targeting-Therapeutics-Market-Company-Competitiveness-Analysis CD-47-Targeting-Therapeutics-Market-Forecast-and-Opportunity

Overview

According to the World Health Organization (WHO), at present, cancer is the second leading cause of death, worldwide. The National Cancer Institute (NCI) has estimated that, by 2030, over 22 million individuals are likely to be diagnosed with various types of cancer, in the US alone. As a result of the growing patient population affected by this disease, there is a rise in the demand for effective treatment modalities. The conventional approaches, such as chemotherapy, surgery and radiation therapy, employed for the treatment of oncological indication(s) are considered to be inadequate, specifically for late-stage cancers. Therefore, in recent years, the focus of the research community has shifted towards the development of novel treatment modalities, such as T- cell immunotherapies, that exhibit high efficacy. However, certain limitations are associated with the aforementioned class of therapies as well; they have been demonstrated to have off-target and toxic side effects, including cytokine release syndrome and neurotoxicity. This has further led to significant research initiatives aimed at identifying target specific drug candidates. Among such initiatives, CD47, owing to its increased expression on the surface of cancer cells, has emerged as a cancer immune checkpoint biomarker. Published literature further indicates that tumor growth and metastasis can be inhibited by blocking the interaction between CD47 and the signal-regulating protein alpha (SIRPα).

Currently, there are no approved therapies based on the inhibition of CD47 / SIRPα pathway for advanced stage oncological indication(s), including myelodysplastic syndromes (MDS), non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). Drug developers across the world claim to be evaluating several therapeutics, having dual specificities, in order to enhance the efficacy and expand the number of target modalities. In other words, candidates capable of targeting biomarkers, such as HER2, PD-L1, CD-38, CD-40 and CD-20, in addition to CD47, are being investigated across several studies. Even though majority of the drug candidates are currently in preclinical / initial clinical stages, developers are optimistic regarding the therapeutic potential of this emerging class of drugs. Validation of the efficacy of anti-CD47 therapeutics as a promising treatment for oncological indications can be further asserted through the rapidly growing number of research publications, patents and clinical trials focused on this subject. We believe that this niche, but upcoming market, is poised to witness healthy growth over the next decade, with pioneers in the field likely to benefit from the first-to-market advantage. 

The “CD47 Targeting Therapeutics Market by Target Disease Indication (Acute Myeloid Leukemias, Non-Hodgkin Lymphoma, Colorectal Cancers, Diffuse Large B-cell Lymphoma, Myelodysplastic Syndromes, Non-Small Cell Lung Cancers, Ovarian Epithelial Cancer, Oral Muscositis, Small Cell Lung Cancers), Type of Molecule (Biologics and Small Molecule) Key Players and Key Geographical Regions (US, France, Germany, Italy, Spain, UK, Australia, China, India and Israel): Industry Trends and Global Forecasts, 2021-2035”  report features an extensive study of the current landscape, offering an informed opinion on the likely adoption of CD47 targeting therapeutics in the healthcare industry, over the next 15 years. The report features an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this domain. Amongst other elements, the report features:

  • A detailed overview of the current market landscape of CD47 targeting therapeutics, along with information on several relevant parameters, such as phase of development (clinical and preclinical), target disease indication(s), therapeutic area (hematological malignancies, dermatological disorders, solid tumors, unspecified oncological disorders, and other disorders), target molecule, type of molecule (biological and small molecules), type of therapy (monotherapies, and combination therapies), type of biologic (monoclonal antibody, bi-specific antibody, recombinant fusion protein, peptide), route of administration (intravenous, subcutaneous, and intraperitoneal), and special drug designation awarded (if any). In addition, it presents details of the companies engaged in the development of CD47 targeting therapeutics, as well as information on their year of establishment, company size (in terms of employee count), and location of respective headquarters.
  • Elaborate profiles of key players engaged in the development of CD47 targeting therapeutics. Each profile features a brief overview of the company, details on its drug candidates, financial information (if available), recent developments and an informed future outlook.
  • A detailed analysis of completed, ongoing and planned clinical trials of various CD47 targeting therapeutics, based on several relevant parameters, such as trial registration year, number of patients enrolled, gender of patients enrolled, trial phase, recruitment status and study design, leading sponsors / collaborators, most active players (in terms of number of trials conducted), type of organization, popular therapeutic areas, and regional distribution of trials. 
  • A detailed review of close to 600 peer-reviewed, scientific articles related to research on CD47 targeting therapies over the past few years, based on several relevant parameters, such as year of publication, type of publication, therapeutic area, target indication and key journals (in terms of number of articles published).
  • An analysis of the recent partnerships inked between various players engaged in the development of CD47 targeting therapies, during the period 2016-2021, based on several relevant parameters, such as number of partnership instances, type of partnerships, regional distribution (continent and country-wise) and most active players (in terms of number of partnership).
  • A detailed analysis of various investments, such as venture capital financing, debt financing, grants / awards, capital raised from IPOs and subsequent offerings that were undertaken by companies engaged in this domain, during the period 2016-2021.
  • An analysis highlighting the key opinion leaders (KOLs) in this domain. It features a 2×2 matrix assessing the relative experience of KOLs shortlisted based on their contributions (in terms of involvement in various clinical studies) in this domain, and a schematic world map representation, indicating the geographical location of eminent scientists / researchers engaged in the development of CD47-based therapies.
  • An analysis highlighting various social media trends (Twitter), along with information on prominent accounts, popular keywords and hashtags, as well as year and number of tweets added by players engaged in the development of CD47-based therapies.
  • An analysis of the companies engaged within this domain, featuring a 3-D bubble chart analysis of different peer groups (North America, Europe and Asia-Pacific), based on various parameters, such as pipeline strength, portfolio diversity and portfolio strength
  • An analysis of big pharma players engaged in this domain, featuring a wind rose chart based on several relevant parameters, such as number of therapeutics under development, phase of development, line of therapy, number of indications targeted and years of experience.
  • An analysis of the start-ups (established between 2011-2020; less than 200 employees) engaged in the development of CD47 based therapeutics, based on several parameters, such as number of candidates in discovery, preclinical and clinical phases of development, number of indications targeted, amount raised, number of investors, type of funding and number of deals inked.

One of the key objectives of the report was to estimate the existing market size and future growth opportunity associated with CD47 targeting therapeutics developers, over the next 15 years. Further, we have provided an informed estimate of the market’s evolution, during the period 2021-2035, based on several relevant parameters, such as adoption trends, and expected price variations for these products. The report features the likely distribution of the current and forecasted opportunity within the CD47 targeting therapeutics market across [A] target disease indication (acute myeloid leukemias, non-Hodgkin lymphoma, colorectal cancers, diffuse large b-cell lymphoma, myelodysplastic syndromes, non-small cell lung cancers, ovarian epithelial cancer, oral muscositis, small cell lung cancers), [B] type of molecule (biologics and small molecules), [C] key players and [D] key geographical regions (US, France, Germany, Italy, Spain, UK, Australia, China, India and Israel). In order to account for future uncertainties and to add robustness to our model, we have provided three forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry’s growth. 

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

Key Questions Answered

  • Who are the leading players engaged in the development of CD47 targeting therapeutics?
  • Which are the key drugs being developed across early and late stages of development?
  • Which companies are actively involved in conducting clinical trials for their therapeutics? 
  • What is the evolving trend related to the focus of publications related to CD47 targeting therapeutics?
  • What kind of partnership models are commonly adopted by industry stakeholders? 
  • Who are the key investors in this domain? 
  • Who are the key opinion leaders / experts in this field?
  • What are the evolving social media trends related to CD47 targeting therapeutics?
  • What are the different initiatives undertaken by big pharma players for the development of CD47 therapeutics in the recent past? 
  • How is the current and future opportunity likely to be distributed across key market segments?

Contents

Chapter Outlines

Chapter 2 is an executive summary of the key insights captured in our research. It offers a high-level view on the current state of CD47 targeting therapeutics market and its likely evolution in the short to mid-long term. 

Chapter 3 provides a general introduction to the CD47 gene and associated pathways in the human cells. In addition, it features information on the historical timeline and different areas of applications that have been identified. It also features an elaborate description of pathways that are activated during the phagocytosis process. Further, it highlights the potential side effects, clinical features and therapeutic benefits of targeting CD47 / SIRPAα pathways for the treatment of various oncological indications.

Chapter 4  includes a detailed analysis of the current market landscape of CD47 targeting therapeutics, along with information on several parameters, such as phase of development (clinical and preclinical), target disease indication(s), therapeutic area (hematological malignancies, dermatological disorders, solid tumors, unspecified oncological disorders, and other disorders), target molecule, type of molecule (biological and small molecules), type of therapy (monotherapies, and combination therapies), type of biologic (monoclonal antibody, bi-specific antibody, recombinant fusion protein, peptide, antibodies, bi-functional fusion protein, fusion protein, protein), SIRPA toll-like receptor agonist antibody conjugate (TRAAC)), route of administration (intravenous, subcutaneous, and intraperitoneal), and special drug designation awarded (if any)

Chapter 5 highlights the companies engaged in the development of CD-47 targeting therapeutics, along with information on their year of establishment, company size (in terms of employee count) and location of respective headquarters.

Chapter 6 features elaborate profiles of key players engaged in the development of CD47 targeting therapeutics. Each profile features a brief overview of the company, on its drug candidates, financial information (if available), recent development and an informed future outlook.

Chapter 7 includes a detailed analysis of more than 70 completed, ongoing and planned clinical trials of various CD47 targeting therapeutics, based on several relevant parameters, such as trial registration year, number of patients enrolled, gender of patients enrolled, trial phase, recruitment status and study design, leading sponsors / collaborators, most active players (in terms of number of trials conducted), type of organization, popular therapeutic areas and regional distribution of trials.

Chapter 8 includes a detailed analysis of close to 600 peer-reviewed, scientific articles related to research on CD47 targeting therapies over the past few years, based on several relevant parameters, such as year of publication, type of publication, therapeutic area, target indication and key journals (in terms of number of articles published).


Chapter 9 provides an analysis of the recent partnerships inked between various players engaged in the development of CD47 targeting therapies, during the period 2016-2021, based on several relevant parameters such as number of partnership instances, type of partnerships, regional distribution (continent and country-wise) and most active players (in terms of number of partnership instances)

Chapter 10 includes a detailed analysis of various investments, such as venture capital financing, debt financing, grants / awards, capital raised from IPOs and subsequent offerings that were undertaken by companies engaged in this domain, during the period 2016-2021.

Chapter 11 provides an analysis highlighting the key opinion leaders (KOLs) in this domain. It features a 2×2 matrix assessing the relative experience of KOLs shortlisted based on their contributions (in terms of involvement in various clinical studies) in this domain, and a schematic world map representation, indicating the geographical location of eminent scientists / researchers engaged in the development of CD47-based therapies.

Chapter 12 provides an analysis highlighting various social media trends (Twitter), along with information on prominent accounts, popular keywords and hashtags, as well as year and number of tweets added by players engaged in the development of CD47-based therapies. 

Chapter 13 provides an analysis of the companies engaged within this domain, featuring a 3-D bubble chart analysis of different peer groups (North America, Europe and, Asia-Pacific), based on various parameters, such as pipeline strength, portfolio diversity and portfolio strength. 

Chapter 14 includes an analysis of big pharma players engaged in this domain, featuring a wind rose chart based on several relevant parameters, such as number of therapeutics under development, phase of development, line of therapy, number of indications targeted and years of experience. 
Chapter 15 includes an analysis of the start-ups (established between 2011-2020; less than 200 employees) engaged in the development of CD47 based therapeutics, based on several parameters, such as number of candidates in discovery, preclinical and clinical phases of development, number of indications targeted, amount raised, number of investors, type of funding and number of deals inked. 

Chapter 16 presents an insightful market forecast analysis, highlighting the likely growth of CD47 targeting therapeutics market till 2035. We have segmented market across [A] target disease indication (acute myeloid leukemias, CD20 positive non-hodgkin lymphoma, colorectal cancers, diffuse large b-cell lymphoma, myelodysplastic syndromes, non-small cell lung cancers, ovarian epithelial cancer, oral muscositis, small cell lung cancers), [B] type of molecule (biologics and small molecule), [C] key players and [D] key geographical regions (US, France, Germany, Italy, Spain, UK, Australia, China, India and Israel).

Chapter 17 is an appendix, which contains the list of companies and organizations mentioned in the report.

Table Of Contents

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Key Questions Answered
1.4. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION
3.1. Chapter Overview
3.2. Key Historical Events related to CD47 Targeting Therapies
3.3. Application Areas
3.4. Mechanism of Action
3.5. Associated Side Effects and Likely Solutions 
3.6. Key Features
3.7. Target Indications
3.8. Future Outlook

4. MARKET OVERVIEW
4.1. Chapter Overview
4.2. CD-47 Targeting Therapeutics: Market Landscape
4.2.1. Analysis by Type of Molecule
4.2.2. Analysis by Target Protein
4.2.3. Analysis by Type of Biologic
4.2.4. Analysis by Route of Administration
4.2.5. Analysis by Type of Molecule and Route of Administration
4.2.6. Analysis by Line of Treatment
4.2.7. Analysis by Phase of Development
4.2.8. Analysis by Therapeutic Area
4.2.9. Analysis by Target Indication
4.2.10. Analysis by Type of Therapy
4.3. CD-47 Therapeutics: Developer Landscape
4.3.1. Analysis by Year of Establishment
4.3.2. Analysis by Company Size
4.3.3. Analysis by Location of Headquarters
4.3.4. Analysis by Number of Pipeline Candidates
4.3.5. Analysis by Phase of Development
4.3.6 Analysis by Regional Strength
4.3.7. Analysis by Company Size and Location of Headquarters
4.3.8. Analysis by Year of Establishment, Company Size and Location of Headquarters

5. COMPANY PROFILES
5.1. Abpro
5.1.1. Company Overview
5.1.2. Financial Information
5.1.3. Product Portfolio
5.1.4. Recent Developments and Future Outlook

5.2. ALX Oncology
5.2.1. Company Overview
5.2.2. Financial Information
5.2.3. Product Portfolio
5.2.4. Recent Developments and Future Outlook

5.3. Apmonia Therapeutics
5.3.1. Company Overview
5.3.2. Financial Information
5.3.3. Product Portfolio
5.3.4. Recent Developments and Future Outlook

5.4. Arch Oncology
5.4.1. Company Overview
5.4.2. Financial Information
5.4.3. Product Portfolio
5.4.4. Recent Developments and Future Outlook

5.5. Aurigene
5.5.1. Company Overview
5.5.2. Financial Information
5.5.3. Product Portfolio
5.5.4. Recent Developments and Future Outlook

5.6. Bristol Myers Squibb
5.6.1. Company Overview
5.6.2. Financial Information
5.6.3. Product Portfolio
5.6.4. Recent Developments and Future Outlook

5.7. EpicentRx
5.7.1. Company Overview
5.7.2. Financial Information
5.7.3. Product Portfolio
5.7.4. Recent Developments and Future Outlook

5.8. Forty Seven
5.8.1. Company Overview
5.8.2. Financial Information
5.8.3. Product Portfolio
5.8.4. Recent Developments and Future Outlook

5.9. ImmuneOncia Therapeutics
5.9.1. Company Overview
5.9.2. Financial Information
5.9.3. Product Portfolio
5.9.4. Recent Developments and Future Outlook

5.10. ImmuneOnco Biopharmaceuticals
5.10.1. Company Overview
5.10.2. Financial Information
5.10.3. Product Portfolio
5.10.4. Recent Developments and Future Outlook

5.11. Innovent Biologics
5.11.1. Company Overview
5.11.2. Financial Information
5.11.3. Product Portfolio
5.11.4. Recent Developments and Future Outlook

5.12. KAHR Medical
5.12.1. Company Overview
5.12.2. Financial Information
5.12.3. Product Portfolio
5.12.4. Recent Developments and Future Outlook

5.13. Light Chain Bioscience
5.13.1. Company Overview
5.13.2. Financial Information
5.13.3. Product Portfolio
5.13.4. Recent Developments and Future Outlook

5.14. Morphiex
5.14.1. Company Overview
5.14.2. Financial Information
5.14.3. Product Portfolio
5.14.4. Recent Developments and Future Outlook

5.15. Trillium Therapeutics
5.15.1. Company Overview
5.15.2. Financial Information
5.15.3. Product Portfolio
5.15.4. Recent Developments and Future Outlook

6. CLINICAL TRIAL ANALYSIS
6.1. Chapter Overview
6.2. Scope and Methodology
6.3. CD-47 Targeting Therapeutics: List of Clinical Trials
6.3.1. Analysis by Trial Status
6.3.2. Analysis by Trial Registration Year
6.3.3. Analysis by Trial Status and Trial Registration Year
6.3.4. Analysis by Number of Patients Enrolled and Phase of Development
6.3.5. Analysis by Type of Sponsor
6.3.6. Analysis by Target Patient Group
6.3.7. Analysis by Study Type
6.3.8. Analysis by Type of Masking
6.3.9. Analysis by Type of Interventional Model
6.3.10. Analysis by Primary Purpose of Trial
6.3.11. Analysis of Enrolled Patient Population by Geography

7. PUBLICATION ANALYSIS
7.1. Chapter Overview
7.2. Scope and Methodology
7.3. CD-47 Therapeutics: List of Publications
7.3.1. Analysis by Year of Publication
7.3.2. Analysis by Type of Publication
7.3.3. Analysis by Therapeutic Area
7.3.4. Analysis by Target Indication
7.3.5. Analysis by Affiliation of First Author
7.3.6. Leading Players: Analysis by Number of Publications
7.3.7. Key Journals: Analysis by Number of Publications

8. PARTNERSHIPS AND COLLABORATIONS
8.1. CD-47 Therapeutics: List of Partnerships and Collaborations
8.1.1 Cumulative Analysis by Year, 2015-2021
8.1.1. Analysis by Type of Partnership
8.1.2. Analysis by Year and Type of Partnership
8.1.3. Analysis by Type of Partner
8.1.4. Analysis by Year by Type of Partner
8.1.5. Analysis by Type of Partner andType of Partnership
8.1.6. Most Active Players: Analysis by Number of Partnerships
8.1.7. Analysis by Region (Continent-wise)
8.1.7.1 Intercontinental and Intracontinental Agreements
8.1.8. Analysis by Region (Country-wise)
8.1.8.1 Local and International Agreements

9. FUNDING AND INVESTMENTS
9.1. CD-47 Therapeutics: List of Funding and Investments
9.1.1. Cumulative Analysis of Funding Instances by Year, 2015–2021
9.1.5. Analysis of Number of Instances by Type of Funding
9.1.2. Analysis of Instances by Year and Type of Funding, 2015–2021
9.1.3. Cumulative Analysis of Amount Invested by Year, 2015–2021
9.1.4. Analysis of Amount Invested by Year and Type of Funding, 2015–2021
9.1.6. Analysis of Amount Invested by Type of Funding
9.1.7. Analysis of Instances by Geography
9.1.8. Analysis of Total Amount Invested by Geography
9.1.9. Most Active Players: Analysis by Number of Instances
9.1.10. Most Active Players: Analysis by Amount Raised
9.1.11. Most Active Investors: Analysis by Number of Funding Instances,

10. KEY OPINION LEADERS
10.1. CD-47 Therapeutics: List of Key Opinion Leaders
10.1.1. Analysis by Type of Current Organization
10.1.2. Analysis by Geography
10.1.2.1. Analysis by Region (Continent-wise Distribution)
10.1.2.2. Analysis by Region (Country-wise Distribution)
10.1.3. Analysis by Number of Investigators and Current Organization
10.1.4. Analysis by Qualification of KOL
10.1.5. Comparison of KOL Activeness v/s Strength (Scatter Plot)
10.1.6. Comparison of Roots Analysis Score v/s Third Party Score
10.1.7. Prominent Players: Comparison of Roots Analysis Score v/s Third Party Score
10.1.8. Analysis by Region
10.1.9. Most Active Key Opinion Leaders: Comparison of Professional Network v/s Academic Strength

11. EMERGING TRENDS ON SOCIAL MEDIA
11.1. Chapter Overview
11.2. CD-47 Therapeutics: Trends on Twitter
11.2.1. Historical Trend in Volume of Tweets
11.2.2. Trending Words / Phrases on Twitter
11.2.3. Most Popular Drugs on Twitter
11.2.4. Most Prolific Authors on Twitter
11.2.5. Most Popular Indications 

12. COMPANY COMPETITIVENESS ANALYSIS
12.1. Chapter Overview
12.2. Methodology and Key Parameters
12.3. CD-47 Therapy Developers
12.3.1. Peer Group 1: Players based in North America
12.3.2. Peer Group 2: Players based in Europe
12.3.3. Peer Group 3: Players based in Asia-Pacific

13. BIG PHARMA PLAYERS
13.1. Chapter Overview
13.2. Methodology and Key Parameters
13.2.1. Analysis by Pipeline Strength
13.2.2. Analysis by Funding and Investments
13.2.3. Analysis by Partnerships
13.2.4. Analysis by Clinical Trials
13.2.5. Summary of Big Pharma Activity 

14. START-UP HEALTH INDEXING
14.1. Chapter Overview
14.2. Start-ups Focused on CD-47 Targeting Therapeutics
14.3. Methodology and Key Parameters 
14.4.1 Analysis by Location of Headquarters 
14.2.3. Analysis by Pipeline Maturity
14.2.4. Analysis by Pipeline Strength
14.2.5. Analysis by Indication Diversity
14.2.6. Analysis by Capital Accrued through Investments
14.2.7. Analysis by Number of Investors
14.2.8. Analysis by Partnership Activity
14.2.9. Start-ups Health Indexing: Roots Analysis Perspective

15. MARKET SIZING AND OPPORTUNITY ANALYSIS
15.1. Chapter Overview
15.2. Scope and Limitations
15.3. Key Assumptions and Forecast Methodology
15.4. Global CD-47 Targeting Therapeutics Market, 2021-2035

15.5. CD-47 Targeting Therapeutics Market, 2021-2035: Analysis by Target Indication
15.5.1. CD-47 Targeting Therapeutics Market for Acute Myeloid Leukemia
15.5.2. CD-47 Targeting Therapeutics Market for Colorectal Neoplasms
15.5.3. CD-47 Targeting Therapeutics Market for Diffuse-Large Cell Lymphoma 
15.5.4. CD-47 Targeting Therapeutics Market for Myelodysplastic Syndromes
15.5.5. CD-47 Targeting Therapeutics Market for Non-Hodgkin Lymphoma
15.5.6. CD-47 Targeting Therapeutics Market for Non-Small Cell Lung Cancer 
15.5.7. CD-47 Targeting Therapeutics Market for Oral Muscositis 
15.5.8. CD-47 Targeting Therapeutics Market for Ovarian Epithelial Cancer 
15.5.9. CD-47 Targeting Therapeutics Market for Small Cell Lung Cancer 

15.6. CD-47 Targeting Therapeutics Market, 2021-2035: Analysis by Type of Molecule
15.6.1. CD-47 Targeting Therapeutics Market for Biologics
15.6.2. CD-47 Targeting Therapeutics Market for Small Molecules

15.7. CD-47 Targeting Therapeutics Market, 2021-2035: Analysis by Geography
15.7.1. CD-47 Targeting Therapeutics Market in the US
15.7.2. CD-47 Targeting Therapeutics Market in France
15.7.3. CD-47 Targeting Therapeutics Market in Germany 
15.7.4. CD-47 Targeting Therapeutics Market in Italy 
15.7.5. CD-47 Targeting Therapeutics Market in Spain
15.7.6. CD-47 Targeting Therapeutics Market in UK
15.7.7. CD-47 Targeting Therapeutics Market in Australia
15.7.8. CD-47 Targeting Therapeutics Market in China 
15.7.9. CD-47 Targeting Therapeutics Market in India
15.7.10. CD-47 Targeting Therapeutics Market in Israel 

15.8. Drug-wise Sales Forecast
15.8.1. CPO-127 (Conjupro biotherapeutics)
15.8.1.1. Target Patient Population
15.8.1.2. Value Creation Analysis

15.8.2. DSP-107 (KAHR Medical)
15.8.2.1. Target Patient Population
15.8.2.2. Value Creation Analysis

15.8.3. IBI188 (Innovent Biologics)
15.8.3.1. Target Patient Population
15.8.3.2. Value Creation Analysis

15.8.4. Magrolimab (Forty Seven)
15.8.4.1. Target Patient Population
15.8.4.2. Value Creation Analysis

15.8.5. RRX-001 (EpicentRx)
15.8.5.1. Target Patient Population
15.8.5.2. Value Creation Analysis

16. APPENDIX 1: LIST OF COMPANIES AND ORGANIZATIONS

List Of Tables

Table 4.1. List of CD-47 Targeting Therapeutics
Table 4.1. List of CD-47 Targeting Therapeutic Developers
Table 6.1. CD-47 Targeted Therapeutics: List of Clinical Trials
Table 7.1. CD-47 Targeted Therapeutics: List of Publications
Table 8.1. CD-47 Targeted Therapeutics: List of Partnerships and Collaborations
Table 9.1. CD-47 Targeted Therapeutics: List of Funding and Investments
Table 10.1 CD-47 Targeted Therapeutics: List of Key Opinion Leaders
Table 11.1 CD-47 Targeted Therapeutics: List of Tweets
Table 14.1 CD-47 Targeted Therapeutics: List of Start-ups
Table 15.1 CD-47 Targeted Therapeutics: List of Forecasted Drugs

List Of Companies

The following companies and organizations have been mentioned in the report.

  1. 3×5 Partners
  2. 3D Medicines (3DMed)
  3. AbbVie
  4. Abpro 
  5. Acerta Pharma
  6. Adage Capital Management
  7. Akeso
  8. Alector
  9. ALX Oncology
  10. Apmonia Therapeutics
  11. Arch Oncology
  12. Ascentage Pharma 
  13. Aurigene Discovery Technologies
  14. Avego Healthcare Capital
  15. Avidity Partners
  16. Beijing Institute of Biotechnology
  17. BIOCAD
  18. Biotech Alliances International
  19. Bio-Thera Solutions
  20. BliNK Biomedical
  21. bluebird bio
  22. Boehringer Ingelheim
  23. Boxer Capital
  24. Bristol-Myers-Squibb
  25. BVF Partners
  26. California Institute for Regenerative Medicine (CIRM) 
  27. Cancer Focus Fund
  28. Chia Tai Tianqing Pharmaceutical Group
  29. Chinese Academy of Sciences
  30. Chinook Therapeutics
  31. Clarus Ventures 
  32. Conjupro Biotherapeutics
  33. Cormorant Asset Management
  34. Cowen Healthcare Investments 
  35. DAFNA Capital Management
  36. EcoR1 Capital
  37. Eli Lilly
  38. Elpiscience
  39. Emerson Collective
  40. EMulate Therapeutics
  41. EpicentRx
  42. Eventide Asset Management
  43. Fidelity Management & Research Company
  44. Flerie Invest 
  45. FMB Research and Broadfin 
  46. Foresite Capital
  47. Forty Seven
  48. Gateway Biologics (A subsidiary of ShangPharma)
  49. Genentech
  50. Genmab
  51. Gilead Sciences
  52. GlaxoSmithKline
  53. GV 
  54. Hadasit Bio Holdings
  55. Hanmi Pharmaceuticals
  56. Hatteras Venture Partners
  57. HBM Healthcare Investments
  58. Ichnos Sciences
  59. I-Mab Biopharma
  60. ImmuneOncia Therapeutics
  61. ImmuneOnco Biopharmaceuticals
  62. Innovent Biologics
  63. ISU ABXIS
  64. Janssen
  65. Janus Henderson Investors
  66. K2 HealthVentures
  67. KAHR Medical
  68. Leukemia & Lymphoma Society (LLS) 
  69. Li Cheng Enterprise
  70. Light Chain Bioscience
  71. Lightspeed Venture Partners 
  72. Lightstone Ventures 
  73. Lilly Asia Ventures (LAV)
  74. Logos Capital
  75. Lonza 
  76. LYFE Capital
  77. Lynkcell
  78. MacroGenics
  79. Merck
  80. Mirae Asset Venture Investment
  81. Morphiex Biotherapeutics
  82. Mountain Pacific Venture 
  83. Navigen Pharmaceuticals
  84. New Enterprise Associates
  85. Novartis Institutes for BioMedical Research
  86. Novimmune
  87. Novo Nordisk
  88. Ono Pharmaceutical 
  89. Oriella
  90. OSE Immunotherapeutics
  91. Paradigm Shift Therapeutics
  92. Partner Fund Management
  93. Pavilion Capital 
  94. Peregrine Ventures
  95. Pfizer
  96. PharmAbcine
  97. Piper Sandler 
  98. Point72 Asset Management
  99. QLSF Biotherapeutics
  100. Redmile Group
  101. RiverVest Venture Partners
  102. Roche
  103. Roche Venture Fund
  104. Saiyuan
  105. Samsung BioLogics
  106. Sanquin 
  107. SATT Nord
  108. SciClone Pharmaceuticals
  109. Shanghai Zhangke Lingyi Investment 
  110. Shattuck Labs
  111. Shavit Capital 
  112. Shengzhou Minglang Industrial Development
  113. Shijiazhuang High Tech Zone Puen Guoxin 
  114. Sorrento Therapeutics
  115. Stanford University
  116. Sutter Hill Ventures
  117. SWISS BIOPHARMA MED 
  118. Synthon Biopharmaceuticals
  119. Tallac Therapeutics
  120. TG Therapeutics
  121. Thomas Jefferson University
  122. Trillium Therapeutics
  123. University Medical Center Groningen
  124. venBio 
  125. Venrock Healthcare Capital Partners
  126. Vivo Capital
  127. Vivoryon Therapeutics
  128. Washington University School of Medicine
  129. Waterstone Hanxbio
  130. Xinxiang Medical University
  131. Zai Lab
  132. Zymeworks

PRICING DETAILS

USD 5,499

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print read more

This license grants the right of use of the purchased report by the employees of a business unit at a particular site/office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple read more

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm/enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the read more

Discounts available for multiple report purchases
sales@rootsanalysis.com